PMID: 16625985Apr 22, 2006Paper

Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients

International Journal of Clinical Pharmacology and Therapeutics
H HoldaasJ Denouel

Abstract

To assess the pharmacokinetic interaction between cyclosporine and extended-release fluvastatin (fluvastatin XL), 80 mg for 7 days, in stable renal transplant recipients. This was a single-center, open-label study. 17 renal transplant recipients received their standard cyclosporine therapy (Days 1 - 9) plus a once-daily single oral dose of fluvastatin XL, 80 mg (Days 2 - 8). Blood samples were collected and cyclosporine (whole blood) and fluvastatin (plasma) concentrations determined by radioimmunoassay and HPLC fluorescence detection, respectively. Pharmacokinetic parameters were calculated using non-compartment analysis and fluvastatin results were compared with historical controls. Treatment with fluvastatin XL, 80 mg for 7 days, had no significant effect on either the AUC0-12 (3,644 ng x h/ml in the absence of fluvastatin vs. 3,534 ng x h/ml in the presence of fluvastatin) or the Cmax of cyclosporine (983 ng/ml in the absence of fluvastatin vs. 945 ng/ml in the presence of fluvastatin). Co-administration of fluvastatin XL also had no effect on the tmax, t1/2 or apparent clearance (CL/F) of cyclosporine in renal transplant patients. The AUC and Cmax for fluvastatin XL in the presence of cyclosporine (AUC0-24 1,192 ng. x h/ml...Continue Reading

Citations

May 20, 2008·Cardiovascular Therapeutics·Genovefa D KolovouDennis V Cokkinos
Apr 30, 2005·International Journal of Cardiology·Vincent Launay-VacherGilbert Deray
Mar 1, 2006·Transplantation Proceedings·K MuchaL Paczek
Jul 8, 2016·Journal of Clinical Pharmacology·Mitesh PatelMaciej J Zamek-Gliszczynski
Jan 5, 2008·Skinmed·Noah S Scheinfeld
Jul 10, 2018·Current Vascular Pharmacology·Gabriella RicciFrancesca Cortese
May 14, 2008·Expert Opinion on Pharmacotherapy·Kenneth J McDonald, Alan G Jardine
Mar 3, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Yi-An BiYurong Lai
Jun 4, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Rune AmundsenAnders Asberg
Nov 23, 2011·Pharmacological Reviews·Patrizia GazzerroMaurizio Bifulco
Jul 20, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kazuho SakamotoJunko Kimura
Jan 1, 2010·Biotechnology & Genetic Engineering Reviews·Michael SauerPaola Branduardi
May 20, 2015·Science and Technology of Advanced Materials·Michikazu HaraKeigo Kamata
Apr 22, 2021·Clinical Pharmacology and Therapeutics·Yue XiangLeslie Z Benet

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Pharmacology
Surya P AyalasomayajulaWilliam P Dole
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
H HoldaasAssessment of LEscol in Renal Transplantation (ALERT) Study Investigators
Archives of Internal Medicine
Christie M BallantyneEvan A Stein
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
C M Stirling, C G Isles
© 2022 Meta ULC. All rights reserved